Table 1 Clinical characteristics of XPO1 mutant NSCLC patients with immunotherapy
From: XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
Patient | Study | Histology | Sex | XPO1 mutation (protein change) | Mutation type | TMB (mutations/Mb) | STK11/KEAP1 mutation | OS (months) | OS status |
|---|---|---|---|---|---|---|---|---|---|
A | MSK-TMB | Squamous | Male | c.2461C > G (Q821E) | Missense | 7.87 | No | 18 | Living |
B | MSK-TMB | Adenocarcinoma | Male | c.1087A > G (T363A) | Missense | 22.63 | No | 21 | Living |
C | MSK-TMB | Adenocarcinoma | Male | c.1211C > G (P404R) | Missense | 11.81 | STK11 | 6 | Dead |
D | MSK-TMB | Adenocarcinoma | Female | c.1003C > G (Q335E) | Missense | 10.82 | No | 13 | Living |
E | MSK-TMB | Squamous | Male | XPO1-USP34 fusion | Fusion | 7.87 | No | 19 | Dead |
F | POPLAR | Squamous | Male | c.2977C > G (Q993E) | Missense | 44 | No | 23 | Living |
G | POPLAR | Non-squamous | Female | c.1434G > C (E478D) | Missense | 49 | No | 16 | Dead |
H | OAK | Non-squamous | Male | c.2461C > T (Q821*) | Nonsense | 62 | No | 21 | Living |
I | OAK | Non-squamous | Male | c.1925G > T (G642V) | Missense | 20 | KEAP1 | 4 | Dead |